Pauline Raaschou

Publications
CV
Public outreach and news

Articles

Article: HEALTH SCIENCE REPORTS. 2023;6(11):e1692
Anticoagulant treatment and COVID-19 mortality among older adults living in nursing homes in Sweden
Kananen L; Molnar C; Ansker F; Kozlowska DJ; Hagg S; Jylhava J; Religa D; Raaschou P
Article: BIOETHICS. 2023;37(7):668-673
Should relational effects be considered in health care priority setting?
Gustavsson E; Juth N; Larfars G; Raaschou P; Sandman L
Article: JOURNAL OF MEDICAL ETHICS. 2021;47(9):608-614
Novel drug candidates targeting Alzheimer's disease: ethical challenges with identifying the relevant patient population
Gustavsson E; Raaschou P; Larfars G; Sandman L; Juth N
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2020;76(7):1029-1041
Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort
Ekheden I; Ebrahim F; olafsdottir H; Raaschou P; Wettermark B; Henriksson R; Ye W
Article: ACTA PAEDIATRICA, INTERNATIONAL JOURNAL OF PAEDIATRICS. 2019;108(7):1250-1255
Snus users had high levels of nicotine, cotinine and 3-hydroxycotinine in their breastmilk, and the clearance was slower than in smoking mothers
Nordenstam F; Lundell B; Bonamy A-KE; Raaschou P; Wickstrom R
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 2018;97(11):1373-1380
Maternal snuff use and cotinine in late pregnancy-A validation study
Gunnerbeck A; Raaschou P; Cnattingius S; Bonamy A-KE; Wickstrom R
Article: ANNALS OF INTERNAL MEDICINE. 2018;169(5):291-299
Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis A Nationwide Population-Based Cohort Study
Raaschou P; Soderling J; Turesson C; Askling J
Article: NICOTINE AND TOBACCO RESEARCH. 2017;19(7):797-803
Prenatal Exposure to Snus Alters Heart Rate Variability in the Infant
Nordenstam F; Lundell B; Cohen G; Tessma MK; Raaschou P; Wickstrom R
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(2):386-391
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
Mercer LK; Askling J; Raaschou P; Dixon WG; Dreyer L; Hetland ML; Strangfeld A; Zink A; Mariette X; Finckh A; Canhao H; Lannone F; Zavada J; Morel J; Gottenberg J-E; Hyrich KL; Listing J
Article: THE BMJ. 2016;352:i262
Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden
Raaschou P; Simard JF; Hagelberg CA; Askling J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(12):2137-2143
TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study
Raaschou P; Frisell T; Askling J
Article: THE BMJ. 2013;346:f1939
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
Raaschou P; Simard JF; Holmqvist M; Askling J
Article: LAKARTIDNINGEN. 2013;110(3):82-84
[Observational cohort studies. Overview and some examples from the field of drug safety].
Holmqvist M; Raaschou P; Neovius M; Askling J
Article: ARTHRITIS & RHEUMATOLOGY. 2011;63(7):1812-1822
Does Cancer That Occurs During or After Anti-Tumor Necrosis Factor Therapy Have a Worse Prognosis? A National Assessment of Overall and Site-Specific Cancer Survival in Rheumatoid Arthritis Patients Treated With Biologic Agents
Raaschou P; Simard JF; Neovius M; Askling J
Article: JOURNAL OF OBESITY. 2011;2011:459263-7
Usage, risk, and benefit of weight-loss drugs in primary care.
Forslund T; Raaschou P; Hjemdahl P; Krakau I; Wettermark B
Article: LAKARTIDNINGEN. 2010;107(13-14):910-913
[Anti-obesity agents do not seem to have any beneficial effects. Health centers prescribe preparations haphazardly, according to a medical records study].
Forslund T; Wettermark B; Raaschou P; Hjemdahl P; Krakau I
Article: ARTHRITIS & RHEUMATOLOGY. 2009;60(11):3180-3189
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Coster L; Geborek P; Jacobsson LT; Lindblad S; Rantapaa-Dahlqvist S; Saxne T; Klareskog L
Article: LAKARTIDNINGEN. 2007;104(51-52):3879-3881
[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
Wettermark B; Raaschou P; Forslund T; Hjemdahl P
Article: ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH. 1998;22(6):1185-1189
Modulation of volitional ethanol intake in the rat by central δ-opioid receptors
Franck J; Lindholm S; Raaschou P

All other publications

Editorial comment: JOURNAL OF MEDICAL ETHICS. 2022;48(3):193
The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators
Gustavsson E; Raaschou P; Larfars G; Sandman L; Juth N
Editorial comment: ANNALS OF INTERNAL MEDICINE. 2018;169(5):I-12
Tumor Necrosis Factor Inhibitors and Cancer Relapse.
Thesis / dissertation: 2014
Anti-TNF therapy and malignancy in patients with rheumatoid arthritis : studies on cancer incidence, recurrence and survival
Raaschou, Pauline

Employments

Affiliated to Teaching/Tutoring, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 2023-2026
Affiliated to Research, Department of Medicine, Karolinska Institutet, 2023-2025

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Solna, Karolinska Institutet, 2014
University Medical Degree, Karolinska Institutet, 1998

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI